40 results
10-K
2022 FY
EX-4.7
VYNT
Vyant Bio, Inc.
Annual report
31 Mar 23
12:00am
10-K
2021 FY
EX-4.7
VYNT
Vyant Bio, Inc.
Annual report
30 Mar 22
7:27am
8-K
EX-4.1
VYNT
Vyant Bio, Inc.
5 Apr 21
Report of Independent Registered Public Accounting Firm
5:12pm
10-K
2020 FY
EX-4.14
VYNT
Vyant Bio, Inc.
Annual report
31 Mar 21
6:01am
8-K
EX-4.1
VYNT
Vyant Bio, Inc.
16 Feb 21
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
4:51pm
8-K
EX-4.3
16r e4quy
1 Feb 21
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
5:24pm
8-K
EX-4.1
yywqypup653g6xch
1 Feb 21
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
5:24pm
8-K
EX-4.1
951w8gzq
2 Nov 20
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
4:26pm
425
EX-4.1
c2ge8 zvo9
2 Nov 20
Business combination disclosure
4:24pm
8-K
EX-4.1
18fvlqhnvtgyk3adk 9f
25 Oct 19
Cancer Genetics, Inc. Announces Strategic Transactions
12:00am
8-K
EX-4.1
kyxiscnw6s160
19 Jul 19
Cancer Genetics, Inc. Announces Strategic Transactions
5:30pm
8-K
EX-4.1
m2cvtyc8
29 Jan 19
Unregistered Sales of Equity Securities
5:25pm
8-K
EX-4.1
xely8y1d2zposayxlg
10 Jan 19
Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock
5:04pm
8-K
EX-4.1
3g1lk8sbkph
18 Jul 18
Cancer Genetics Closes $2.625 million Convertible Note Financing
4:18pm
8-K
EX-4.1
rj874ch
5 Jul 18
Entry into a Material Definitive Agreement
4:59pm
8-K
EX-4.1
o8znfm6m308jhywb
8 Dec 17
Cancer Genetics Prices $7.0 Million Registered Direct Offering
12:00am
8-K
EX-4.1
oy0l3e opwq4jjluz6yi
16 Aug 17
Entry into a Material Definitive Agreement
12:00am